Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer (vol 5, e225394, 2022)

被引：1
|
作者：
Graf, R. P.
Fisher, V
Weberpals, J.
机构：
来源：
JAMA NETWORK OPEN | 2022年 / 5卷 / 05期
关键词：
D O I：
10.1001/jamanetworkopen.2022.13901
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Huang, Ahong
    Wang, Li
    Baser, Onur
    Miao, Raymond
    BJU INTERNATIONAL, 2018, 121 (06) : 871 - 879
  • [22] ABIRATERONE ACETATE VERSUS ENZALUTAMIDE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER POST CHEMOTHERAPY: COST EFFECTIVENESS ANALYSIS
    He, J.
    Li, T.
    Saadi, R.
    VALUE IN HEALTH, 2013, 16 (07) : A411 - A411
  • [23] Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
    De Laere, B.
    Crippa, A.
    Ghysel, C.
    Ost, P.
    Rajan, P.
    Eklund, M.
    Dirix, L.
    Gronberg, H.
    Lindberg, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] Impact of Abiraterone Acetate and Enzalutamide on Symptom Burden of Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer
    Salem, S.
    Komisarenko, M.
    Timilshina, N.
    Martin, L.
    Grewal, R.
    Alibhai, S.
    Finelli, A.
    CLINICAL ONCOLOGY, 2017, 29 (09) : 601 - 608
  • [25] PSMA-heterogeneity in metastatic castration-resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy
    Derlin, Thorsten
    Riethdorf, Sabine
    Schumacher, Udo
    Lafos, Marcel
    Peine, Sven
    Coith, Cornelia
    Ross, Tobias L.
    Pantel, Klaus
    Bengel, Frank M.
    PROSTATE, 2023, 83 (11): : 1076 - 1088
  • [26] Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?
    Has Simsek, Duygu
    Kuyumcu, Serkan
    Karadogan, Seyfullah
    Oflas, Melis
    Isik, Emine Goknur
    Ozkan, Zeynep Gozde
    Paksoy, Nail
    Ekmekcioglu, Ozgul
    Ekenel, Meltem
    Sanli, Yasemin
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (06) : 680 - 690
  • [27] Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?
    Duygu Has Simsek
    Serkan Kuyumcu
    Seyfullah Karadogan
    Melis Oflas
    Emine Goknur Isik
    Zeynep Gozde Ozkan
    Nail Paksoy
    Ozgul Ekmekcioglu
    Meltem Ekenel
    Yasemin Sanli
    Annals of Nuclear Medicine, 2021, 35 : 680 - 690
  • [28] COST-EFFECTIVENESS OF OLAPARIB VS. RUCAPARIB FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER - THE CANADIAN PERSPECTIVE
    Yanev, I
    Aprikian, A.
    Raizenne, B. L.
    Dragomir, A.
    VALUE IN HEALTH, 2023, 26 (12) : S202 - S202
  • [29] Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naive metastatic castration-resistant prostate cancer in Japan
    Okumura, Hiroyuki
    Inoue, Sachie
    Naidoo, Shevani
    Holmstrom, Stefan
    Akaza, Hideyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (08) : 1319 - 1329
  • [30] Sequencing of chemotherapy and androgen-axis inhibitors (AAIs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Dhawan, Ravinder
    Yang, Tony
    Miao, Raymond
    Hennessy, Daniel
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345